Home Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients
 

Keywords :   


Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients

2014-11-03 11:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection. Results were presented as a poster (#0434) and oral presentation by Dr. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCarmen de Gourville, 267-664-0146orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data study phase patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.11S
24.11
24.115
24.11SR
24.11 RC24.4.5
24.11115+128717dz
24.11lavaSUKALA 3
24.11508A
More »